Zealand Pharma and Helsinn Healthcare Sign a Partnering Agreement for ZP1846, a novel GLP-2 agonist
02-Dec-2008 -
Zealand Pharma A/S and Helsinn Healthcare SA announced that it has signed a partnering agreement, for the development and worldwide commercialization of ZP1846, a GLP-2 (glucagon-like peptide-2) receptor agonist which provides a novel way to treat chemotherapy-induced diarrhea (CID), a ...
chemotherapy
chemotherapy-induced diarrhea
clinical trials
+1